Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. More Details
Average dividend payer and fair value.
Share Price & News
How has Hill-Rom Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HRC's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: HRC underperformed the US Medical Equipment industry which returned 15.2% over the past year.
Return vs Market: HRC underperformed the US Market which returned 12.9% over the past year.
Price Volatility Vs. Market
How volatile is Hill-Rom Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Buy Hill-Rom Holdings, Inc. (NYSE:HRC) For Its Upcoming Dividend?
2 weeks ago | Simply Wall StHill-Rom Holdings (NYSE:HRC) Shareholders Have Enjoyed A 72% Share Price Gain
4 weeks ago | Simply Wall StAre Hill-Rom Holdings's (NYSE:HRC) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Is Hill-Rom Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HRC ($84.46) is trading below our estimate of fair value ($98.75)
Significantly Below Fair Value: HRC is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: HRC is good value based on its PE Ratio (27x) compared to the US Medical Equipment industry average (50.5x).
PE vs Market: HRC is poor value based on its PE Ratio (27x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: HRC is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: HRC is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (4.1x).
How is Hill-Rom Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRC's forecast earnings growth (19.7% per year) is above the savings rate (2.2%).
Earnings vs Market: HRC's earnings (19.7% per year) are forecast to grow slower than the US market (23.1% per year).
High Growth Earnings: HRC's earnings are forecast to grow, but not significantly.
Revenue vs Market: HRC's revenue (3.2% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: HRC's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HRC's Return on Equity is forecast to be high in 3 years time (21%)
How has Hill-Rom Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HRC has a large one-off loss of $96.9M impacting its June 30 2020 financial results.
Growing Profit Margin: HRC's current net profit margins (7%) are lower than last year (7.4%).
Past Earnings Growth Analysis
Earnings Trend: HRC's earnings have grown significantly by 21.3% per year over the past 5 years.
Accelerating Growth: HRC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HRC had negative earnings growth (-2.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (-0.2%).
Return on Equity
High ROE: HRC's Return on Equity (12.6%) is considered low.
How is Hill-Rom Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: HRC's short term assets ($1.4B) exceed its short term liabilities ($941.1M).
Long Term Liabilities: HRC's short term assets ($1.4B) do not cover its long term liabilities ($2.1B).
Debt to Equity History and Analysis
Debt Level: HRC's debt to equity ratio (126%) is considered high.
Reducing Debt: HRC's debt to equity ratio has increased from 78.9% to 126% over the past 5 years.
Debt Coverage: HRC's debt is not well covered by operating cash flow (19.9%).
Interest Coverage: HRC's interest payments on its debt are well covered by EBIT (5.7x coverage).
What is Hill-Rom Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HRC's dividend (1.04%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.66%).
High Dividend: HRC's dividend (1.04%) is low compared to the top 25% of dividend payers in the US market (4.7%).
Stability and Growth of Payments
Stable Dividend: HRC's dividends per share have been stable in the past 10 years.
Growing Dividend: HRC's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27.5%), HRC's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: HRC's dividends in 3 years are forecast to be thoroughly covered by earnings (12.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Groetelaars (53 yo)
Mr. John P. Groetelaars serves as President, Chief Executive Officer and Director of Hill-Rom Holdings Inc. since May 14, 2018. He previously served in a variety of progressive roles at C.R. Bard during hi ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD7.33M) is about average for companies of similar size in the US market ($USD7.39M).
Compensation vs Earnings: John's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|Senior VP & CFO||1.75yrs||US$3.14m||0.0042% |
|Senior VP||4.67yrs||US$1.94m||0.040% |
|Senior VP & President of Front Line Care business||1.75yrs||US$2.02m||0.051% |
|Senior VP & President of Patient Support Systems||3.83yrs||US$2.14m||0% |
|Senior Vice President of Operations||3yrs||no data||no data|
|VP, Controller & CAO||2.33yrs||no data||0.0032% |
|CTO & Senior VP||9.75yrs||no data||no data|
|Chief Information Officer & Senior VP||4.67yrs||no data||no data|
|Senior Vice President of Corporate Development||no data||no data||0.012% |
|Chief Compliance Officer||5.83yrs||no data||no data|
|Vice President of Corporate Communications||no data||no data||no data|
Experienced Management: HRC's management team is considered experienced (3.4 years average tenure).
|Independent Director||10.75yrs||US$270.70k||0.0030% |
|Independent Director||13.17yrs||US$274.70k||no data|
|Independent Chairman of the Board||2.5yrs||US$382.15k||0.0081% |
|Independent Director||3.5yrs||US$281.70k||no data|
|Independent Director||2.92yrs||US$276.45k||no data|
|Independent Director||0.58yr||no data||no data|
|Independent Director||7.5yrs||US$268.70k||no data|
|Independent Director||5.5yrs||US$264.20k||no data|
|Independent Director||3.5yrs||US$267.70k||0.00045% |
|Independent Director||1.33yrs||US$190.71k||no data|
Experienced Board: HRC's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hill-Rom Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Hill-Rom Holdings, Inc.
- Ticker: HRC
- Exchange: NYSE
- Founded: 1969
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$5.626b
- Shares outstanding: 66.61m
- Website: https://www.hillrom.com
Number of Employees
- Hill-Rom Holdings, Inc.
- 130 East Randolph Street
- Suite 1000
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HRC||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jul 1971|
|HB9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 1971|
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical bed ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/22 06:09|
|End of Day Share Price||2020/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.